Breadcrumb Home Business activities Â鶹Éç BioCapital Â鶹Éç Biocapital Portfolio Enliven Therapeutics Enliven Therapeutics Enliven Therapeutics is developing a novel, chronic, oral treatment for patients with sickle cell disease and other haemoglobinopathies. Relateret nyheder om Enliven Therapeutics 14 August 2020 Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease 11 March 2020 IMARA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING 24 October 2018 Imara Announces Presentation at the Annual Sickle Cell and Thalassaemia Conference 11 October 2018 Imara Announces Upcoming Presentation at the 46th Annual National Sickle Cell Disease Association of America (SCDAA) Convention 13 September 2018 Imara Announces CEO Rahul Ballal, Ph.D., Will Present at the 7th Annual Sickle Cell Disease Therapeutic Conference Â鶹Éç BioCapital Invested 2016 IPO in 2020 – ENVL (Nasdaq) Location Boston, Massachusetts, USA
